CA2708407A1 - Humanized anti-human cd34 antibody, the preparation method and uses thereof - Google Patents

Humanized anti-human cd34 antibody, the preparation method and uses thereof Download PDF

Info

Publication number
CA2708407A1
CA2708407A1 CA2708407A CA2708407A CA2708407A1 CA 2708407 A1 CA2708407 A1 CA 2708407A1 CA 2708407 A CA2708407 A CA 2708407A CA 2708407 A CA2708407 A CA 2708407A CA 2708407 A1 CA2708407 A1 CA 2708407A1
Authority
CA
Canada
Prior art keywords
antibody
human
cells
fragment
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2708407A
Other languages
English (en)
French (fr)
Inventor
Yajun Guo
Weizhu Qian
Sheng Hou
Bohua Li
Hao Wang
Jing Ma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHANGHAI GUOJIAN BIO-TECH INSTITUTE
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN 200710094456 external-priority patent/CN101245108B/zh
Application filed by Individual filed Critical Individual
Publication of CA2708407A1 publication Critical patent/CA2708407A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CA2708407A 2007-12-13 2008-12-03 Humanized anti-human cd34 antibody, the preparation method and uses thereof Abandoned CA2708407A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN200710094456.9 2007-12-13
CN 200710094456 CN101245108B (zh) 2007-12-13 2007-12-13 抗人cd34抗体、其制备方法及用途
CN200810043016 2008-01-08
CN200810043016.5 2008-01-08
PCT/CN2008/001963 WO2009079922A1 (en) 2007-12-13 2008-12-03 Humanized anti-cd34 monoclonal antibody, the preparation and uses thereof

Publications (1)

Publication Number Publication Date
CA2708407A1 true CA2708407A1 (en) 2009-07-02

Family

ID=40800709

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2708407A Abandoned CA2708407A1 (en) 2007-12-13 2008-12-03 Humanized anti-human cd34 antibody, the preparation method and uses thereof

Country Status (6)

Country Link
US (1) US20100311955A1 (enExample)
EP (1) EP2233501B1 (enExample)
JP (1) JP2011505810A (enExample)
BR (1) BRPI0821211A2 (enExample)
CA (1) CA2708407A1 (enExample)
WO (1) WO2009079922A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2686418A4 (en) 2011-03-17 2015-04-22 Minerva Biotechnologies Corp METHOD FOR THE PRODUCTION OF PLURIPOTENTAL STEM CELLS
US8785603B2 (en) 2011-05-20 2014-07-22 Siemens Healthcare Diagnostics Inc. Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof
TWI443107B (zh) 2011-12-29 2014-07-01 Ind Tech Res Inst 人源化之抗人類細胞表面抗原ｃｄ３４之單株抗體及其應用
DK3105252T3 (da) 2014-02-12 2019-10-14 Michael Uhlin Bispecifikke antistoffer til anvendelse ved stamcelletransplantation
US10604586B2 (en) * 2016-05-09 2020-03-31 Industrial Technology Research Institute Humanized monoclonal antibody and uses thereof
CN109265547B (zh) * 2018-07-23 2022-07-26 中国科学院微生物研究所 一种抗cd47抗体及其应用
CN111879923A (zh) * 2020-08-06 2020-11-03 深圳科隆生物新材料有限公司 一种可消除hama效应的试剂盒
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
AU2024274792A1 (en) 2023-05-23 2025-10-23 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
WO2025006799A1 (en) 2023-06-27 2025-01-02 Capstan Therapeutics, Inc. Extracorporeal and ex vivo engineering of select cell populations from peripheral blood
CN116970650B (zh) * 2023-09-22 2023-12-08 深圳华大生命科学研究院 一种包膜蛋白组合、含其的靶向病毒载体及制备方法
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods
CN118501458B (zh) * 2024-05-08 2025-09-30 广东省第二人民医院（广东省卫生应急医院） 一种外周血细胞外囊泡表面多种免疫标志物联合检测的试剂盒及方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH11332578A (ja) * 1998-05-25 1999-12-07 Asahi Chem Ind Co Ltd 細胞の分離装置及び分離方法
JPH11332594A (ja) * 1998-05-26 1999-12-07 Asahi Chem Ind Co Ltd Ｃｄ４陽性細胞の分離装置および分離方法
CN1307640A (zh) * 1998-05-25 2001-08-08 旭化成株式会社 细胞分离装置和分离方法
ATE382633T1 (de) * 2000-05-23 2008-01-15 Baxter Healthcare Sa Reagenzien zur zellselektion und verfahren zur anwendung
US8728525B2 (en) * 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
CN101245108B (zh) * 2007-12-13 2013-04-10 上海抗体药物国家工程研究中心有限公司 抗人cd34抗体、其制备方法及用途

Also Published As

Publication number Publication date
EP2233501A4 (en) 2010-12-01
JP2011505810A (ja) 2011-03-03
EP2233501B1 (en) 2012-07-11
BRPI0821211A2 (pt) 2015-06-16
WO2009079922A1 (en) 2009-07-02
EP2233501A1 (en) 2010-09-29
US20100311955A1 (en) 2010-12-09

Similar Documents

Publication Publication Date Title
EP2233501B1 (en) Humanized anti-cd34 monoclonal antibody, the preparation and uses thereof
CN110088133B (zh) 抗独特型抗体及相关方法
CN107955071B (zh) 人源抗人cd47抗体及其编码基因与应用
JP6987640B2 (ja) Ｃｄ３に特異的なヒト化抗体またはその断片
JP7262597B2 (ja) 二重特異性抗体及びその作製方法と使用
JP7384493B2 (ja) 抗ｃｌｌ１抗体およびその使用
CN107880128B (zh) 一种抗cd19的全人源抗体或抗体片段及其方法和应用
US20120329995A1 (en) Novel Lowered Affinity Antibodies And Methods of Making the Same
KR20230167766A (ko) Cd19에 특이적인 항체 및 키메라 항원 수용체
CN115916817A (zh) 针对bcma靶向结合结构域的抗独特型抗体及相关组合物和方法
CN111349163A (zh) 针对cd123的单克隆抗体
AU2020270888A1 (en) CD19 antibodies and methods of using the same
CN113508139A (zh) 结合人lag-3的抗体、其制备方法和用途
EP4458853A1 (en) Development of novel upar single-domain antibody
CN112794907A (zh) 一株全人源抗人huOX40单克隆抗体
EP4245855A1 (en) Anti-tspan8-anti-cd3 bispecific antibody and anti-tspan8 antibody
CN101245108B (zh) 抗人cd34抗体、其制备方法及用途
CN112010972A (zh) 与人lag-3蛋白结合的抗体及其编码基因和应用
CN117586399A (zh) 抗cd28抗体及其应用
CN114075285B (zh) 抗人cd38人源化单克隆抗体及其应用
CN114478770A (zh) 抗体及其制备方法
CN103936858B (zh) 抗cd20抗原的抗体l5h6及其应用
CN101481417A (zh) 抗人cd34人源化抗体、其制备方法及用途
CN114163528A (zh) Cd47结合分子及其应用
CN103897059B (zh) 抗cd20抗原的抗体l5h7及其应用

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20141203